SALT629

SALT629 is an orally active antitubercular agent with potent intramacrophage activity (EC50 = 1.5 μM) . sALT629 shows broad-spectrum anti-Mycobacterium tuberculosis (Mtb) activities across four carbon sources, equipotent efficacy against drug-resistant Mtb, and activity against both slow-replicating and nonreplicating Mtb. sALT629 exhibits synergistic activity when combined with oxazolidinone drugs, such as Linezolid (HY-10394) and Sutezolid (HY-10392) . sALT629 can be used for the research of tuberculosis[1].

Product Specifications

CAS Number

[484026-63-3]

UNSPSC

12352005

Target

Bacterial

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Smiles

O=C(CN1N=NC(C2=CC=C(C=C2)OCC(C)C)=N1)N

Molecular Formula

C13H17N5O2

Molecular Weight

275.31

References & Citations

[1]Yang B, et al. Design, Synthesis, and Biological Evaluation of Tetrazol-2-yl-acetamides as Novel Antitubercular Agents. ACS Med Chem Lett. 2025 Nov 21;16 (12) :2444-2453.